or Try an Advanced Search...

    Pharmaceuticals Segment Stocks List

    Symbol Grade Name % Change
    XPH B SPDR S&P Pharmaceuticals ETF 0.35
    PRGO D Perrigo Company 1.79
    NVO F Novo Nordisk A/S -0.01
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Diabetes Diabetes Care Hormones Pharmaceutical Products Active Pharmaceutical Ingredients Allergy Analgesics Animal Health Anti Diabetic Drugs Biopharmaceutical Cough Dietary Supplement ETF Endocrine System Exchange Traded Fund Feminine Hygiene Gastrointestinal Generic Drug Glucagon Like Peptide 1 Growth Hormone

    Related ETFs - A few ETFs which own one or more of the above listed Pharmaceuticals Segment stocks.

    Symbol Grade Name Weight
    EDEN D iShares MSCI Denmark Capped ETF 22.75
    OZEM D Roundhill GLP-1 & Weight Loss ETF 17.47
    THNR F Amplify Weight Loss Drug & Treatment ETF 13.45
    INAV B Mohr Industry Nav ETF 10.31
    PPH D Market Vectors Pharmaceutical ETF 8.74
    View all Pharmaceuticals Segment ETFs...
    Compare ETFs
    Compare EDEN to THNR Compare INAV to PPH Compare OZEM to THNR

        Pharmaceuticals Segment Stocks Recent News

        Date Stock Title
        Nov 1 NVO Election Day, Fed decision, earnings: What to Watch Next Week
        Nov 1 NVO Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
        Nov 1 NVO Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
        Nov 1 NVO Novo Nordisk's Semaglutide Trial Shows 'Superior Improvement' in Liver Fibrosis, MASH
        Nov 1 NVO Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
        Nov 1 NVO Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
        Nov 1 NVO Novo Nordisk posts Phase 3 win for obesity drug in MASH
        Nov 1 NVO Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
        Nov 1 NVO Novo, with new results, to seek approval for obesity drug in MASH
        Oct 31 NVO Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
        Oct 31 PRGO Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for
        Oct 30 NVO Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
        Oct 30 NVO Eli Lilly plans to begin advertising weight-loss drug Zepbound
        Oct 30 NVO Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
        Oct 30 NVO Novo takes big step toward ending Ozempic, Wegovy shortages
        Oct 30 PRGO Perrigo (PRGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
        Oct 30 NVO Eli Lilly drops, sending Novo lower after Q3 miss
        Oct 30 NVO Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations
        Oct 30 NVO Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of Estimates
        Oct 30 NVO The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Diabetes Diabetes Care Hormones Pharmaceutical Products Active Pharmaceutical Ingredients Allergy Analgesics Animal Health Anti Diabetic Drugs Biopharmaceutical Cough Dietary Supplement ETF Endocrine System Exchange Traded Fund Feminine Hygiene Gastrointestinal Generic Drug Glucagon Like Peptide 1 Growth Hormone
        Pharmaceuticals Segment

        Pharmaceuticals segment is a sector of the healthcare industry that focuses on the research, development, production, and marketing of drugs and other pharmaceutical products. This segment includes companies that manufacture and distribute prescription and over-the-counter drugs, as well as those that provide related services such as contract manufacturing and clinical research.

        Browse All Tags